Genetic alteration and immunohistochemical staining patterns of ovarian high‐grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern

We evaluated p53, KRAS, BRAF and CTNNB1 mutation and p53, WT1, p16 and beta‐catenin expression in 31 ovarian high‐grade serous adenocarcinoma. Twenty‐five (80.6%) tumors contained functional mutations of p53; three frameshift, four nonsense and 19 missense mutations. None of the tumors showed KRAS, BRAF or CTNNB1 mutation. In all 18 tumors with missense mutations, ≥60% of tumor cells were strongly positive for p53 immunostaining whereas all tumors with frameshift or nonsense mutations were completely negative. Missense mutation was correlated with diffuse and strong imunoreaction and frameshift/nonsense mutation was correlated with completely negative immunoreaction (P = 0.000). Tumors with wild‐type p53 revealed a wide range of immunostaining patterns. In 27 (87.1%) and 18 (58.1%) tumors, ≥50% of tumor cells were moderate to strongly positive for WT1 and p16, respectively. A considerable intratumoral heterogeneity for p16 expression was present. None of the tumors demonstrated nuclear beta‐catenin expression. p53 mutations appear to be a powerful molecular marker for ovarian high‐grade serous adenocarcinoma. Using p53 with an appropriate interpretation criteria together with WT1, p16 and beta‐catenin, most of the high‐grade serous adenocarcinoma could be distinguished from other ovarian tumors.     

基于GRACE评分系统的临床分级护理在急性冠状动脉综合征胸痛病人中的应用

目的:探究基于GRACE评分系统的临床分级护理在急性冠状动脉综合征(ACS)胸痛病人中的应用效果。方法:选取2017年12月—2019年12月医院就诊的70例ACS胸痛病人为研究对象,随机分为观察组与对照组各35例。对照组实施常规护理,观察组实施基于GRACE评分系统的临床分级护理。比较两组病人不良心血管事件(MACE)、死亡情况以及护理质量状况。结果:观察组病人MACE总发生率及病死率明显低于对照组(P<0.05);观察组病人直接护理时间明显长于对照组,分级护理合格率、护理措施到位率明显高于对照组,住院时间明显短于对照组(P<0.05)。结论:基于GRACE评分系统的临床分级护理应用于ACS胸痛病人中,可明显减少MACE发生风险,降低病死率,提高护理质量。     

河北省缺血性脑卒中院内诊治时间分布研究

目的:调查河北省急性缺血性脑卒中患者的院内诊治时间分布情况。方法:收集并分析河北省急性缺血性脑卒中患者的院内诊治流程资料并与NINDS推荐时间进行比较。结果:院内诊治中位时间104 min高于推荐的60 min（ P<0.001）;"完成头颅CT扫描-获取CT报告"中位时间30 min高于推荐的20 min（ P<0.001）;"获取头颅CT报告-开始治疗"中位时间43 min高于推荐的15 min（ P<0.001）。通过EMS就诊患者院内诊治中位时间是101 min,低于未采用患者的104 min（ P=0.01）;三级医院院内诊治中位时间是105 min,迟于二级医院的99 min （ P<0.05）。 结论:河北省急性缺血性脑卒中院内救治延迟现象严重。获取头颅CT报告到开始溶栓治疗这一环节是造成院内延迟的最主要环节。通过EMS就诊可以缩短院内救治时间;二级医院相比三级医院院内延迟情况较轻。     

Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.

AIMS: Prior studies suggest that acute coronary syndromes (ACSs) are associated with endothelial activation and that this is of prognostic significance. We hypothesized that endothelial activation, as measured by a rise in von Willebrand Factor (DeltavWF), was influenced by the thrombolysis in myocardial infarction flow grade (TFG), the corrected TIMI frame count (CTFC) and the choice of anticoagulant therapy after fibrinolysis in ST elevation myocardial infarction (STEMI). METHODS AND RESULTS: Data were drawn from the enoxaparin and tenecteplase tissue plasminogen activator (TNK-tpa) with or without GPIIb/IIIa inhibitor as the reperfusion strategy in the STEMI trial (ENTIRE-TIMI 23). Three hundred and fourteen patients had serial measurements of vWF (baseline and 48-72 h) and angiographic data available. TFG<3 (P=0.0042) or CTFC>/=40 at 60 min (P=0.0035) were associated with a higher DeltavWF. DeltavWF >/=75th percentile was associated with a higher incidence of death or myocardial infarction (MI) at 30 days, compared with <75th percentile (11.2 vs. 4.1%, P=0.027). Enoxaparin independently reduced the DeltavWF (P=0.019) and also the composite of death or MI (OR 0.33, 95% CI 0.12-0.91, P=0.03) compared with unfractionated heparin. CONCLUSION: In STEMI treated by fibrinolysis, coronary flow at 60 min and choice of adjunctive anticoagulant appear to be independent determinants of DeltavWF. Enoxaparin is independently associated with a reduction in DeltavWF and a reduction in death or MI. The clinical benefits of enoxaparin as an adjunctive treatment in STEMI may be mediated in part by a reduction in vWF release.     

高分级前列腺上皮内瘤和前列腺癌中Ezrin的表达及意义

目的探讨埃兹蛋白（Ezrin）在高分级前列腺上皮内瘤（HGPIN）及前列腺癌（CAP）中的表达及意义。方法采用免疫组化SP法检测44例CaP、12例HGPIN、20例前列腺增生（BPH）及10例正常前列腺（NP）组织中Ezrin的表达。结果31例（70．45％）CaP中Ezrin呈中等或强表达，12例HGPIN中Ezrin均呈弱或中等表达．20例BPH和10例NP中Ezrin没有或星弱表达。在CaP中。Gleason评分（GS）8～10分组的Ezrin表达明显高于7分组和5～6分组（P〈0．05），7分组Ezrin表达明显高于5～6分组（P〈0．05）。结论Ezrin的表达可能与CaP的发生有关，其对诊断HGPIN和判断CaP的转移及预后有重要意义。     

Is mitochondrial DNA copy number a good prognostic marker in resectable pancreatic cancer?

Background

The aim of this prospective study was to investigate mitochondrial DNA (mtDNA) copy number in a group of resectable pancreatic cancer (PC) tumor tissues and adjacent normal pancreatic tissues, and to explore the correlation between the mtDNA content in tissues and the clinicopathological parameters and the overall survival.